Table 1.
Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | |
---|---|---|---|---|---|
Age (years) | 86 | 67 | 63 | 83 | 86 |
Gender | M | M | M | F | F |
Weight (Kg) | 68 | 65 | 72 | 49 | 60 |
BMI > 30 | – | – | – | – | – |
Hypertension | + | – | – | + | – |
Diabetes | + | – | – | – | + |
Heart failure | + | – | – | + | – |
COPD | + | + | – | – | + |
Active cancer | – | – | – | – | – |
Chronic renal failure | + | – | – | – | – |
Anticoagulant drug | Rivaroxaban | Edoxaban | Apixaban | Edoxaban | Warfarin |
Anticoagulant dose | 15 mg day | 60 mg day | 5 mg BID | 30 mg day | |
Plasma drug concentration ng/ml | 68 (LloD: 25) | 54 (LloD: 20) | 48 (LloD: 25) | 62 (LloD: 20) | |
Indication to anticoagulation | AF | Previous PE | Previous PE | AF | AF |
PE distribution | Segmental | Segmental | Subsegmental | Subsegmental | Subsegmental |
ARDS severity at admission | Mild | Severe | Mild | Severe | Mild |
PaO2/FIO2 ratio | 187 | 93 | 178 | 88 | 190 |
PLT count x103 | 283 | 116 | 160 | 269 | 215 |
CRP mg/l (nv: <5) | 70.5 | 82 | 33.2 | 321 | 27.3 |
D-dimer µg/ml (nv: 0.5) | 3.99 | 18.4 | 7.2 | 0.27 | 1.7 |
LDH U/l (nv: <248) | 234 | 786 | 214 | 447 | 358 |
INR | 1.85 | 1.03 | 1.18 | 2.69 | 2.33 |
APTT (nv: < 1.2) | 1.37 | 0.99 | 1.01 | 1.59 | 1.62 |
TTr (nv: <1.2) | 1.10 | 1.3 | 1.60 | 1.2 | 0.9 |
Fibrinogen ml/dl (nv: < 200) | 348 | 476 | 365 | 286 | 210 |
Creatinine mg/dl (nv: < 1.18) | 1.28 | 1.09 | 0.86 | 0.74 | 0.6 |
eGFR (mL/min) | 39.8 | 60.5 | 89 | 44.6 | 63.8 |
BMI body mass index, AF atrial fibrillation, PE pulmonary embolism, ARDS acute respiratory distress syndrome, PaO2 arterial partial pressure of oxygen, FIO2 fraction of inspired oxygen, PLT platelet, CRP C-reactive protein, LDH lactate dehydrogenase, INR international normalized ratio, APTT activated partial thromboplastin time, TTr thrombin time ratio, LloD lower limit of detection, eGFR estimated glomerular filtration rate